Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18169491 | 1.00 | APLNR (0.40) | APLNRFFAR3LMNAGRM2GRM3 | |
| SCHEMBL20000454 | 1.00 | APLNR (0.40) | APLNRFFAR3LMNAGRM2GRM3 | |
| SCHEMBL15248834 | 0.89 | GRM2 (0.47) | APLNRFFAR3LMNAGRM2GRM3 | |
| SCHEMBL17893129 | 0.89 | GRM2 (0.47) | APLNRFFAR3LMNAGRM2GRM3 | |
| SCHEMBL17893128 | 0.89 | GRM2 (0.47) | APLNRFFAR3LMNAGRM2GRM3 | |
| SCHEMBL16887593 | 0.84 | TP53 (0.42) | FFAR3NPSR1MAPTGAAHTT | |
| SCHEMBL9044623 | 0.84 | FFAR3 (0.34) | FFAR3LMNANPSR1MAPTMEN1 | |
| SCHEMBL16875305 | 0.84 | TP53 (0.42) | FFAR3NPSR1MAPTGAAHTT | |
| SCHEMBL16875576 | 0.84 | TP53 (0.42) | FFAR3NPSR1MAPTGAAHTT | |
| SCHEMBL20855519 | 0.82 | SMN1; SMN2 (0.40) | FFAR3TDP1NPSR1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340532-A1 | HETEROCYCLIC COMPOUND CCR4 INHIBITOR AND USER THEREOF | XIZANG HAISCO PHARMACEUTICAL CO LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| EP-4534534-A1 | HETEROCYCLIC COMPOUND CCR4 INHIBITOR AND USER THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025059577-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2023232130-A1 | HETEROCYCLIC COMPOUND CCR4 INHIBITOR AND USER THEREOF | 西藏海思科制药有限公司 | 2023-12-07 | — | — | WO | disclosed |
| EP-3240572-B1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20190119282-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2019-04-25 | — | — | US | disclosed |
| US-10087188-B2 | Benzamide imidazopyrazine Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-10-02 | — | — | US | disclosed |
| US-10030024-B2 | Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-24 | — | — | US | disclosed |
| WO-2018057588-A1 | FURO[3,2-B]PYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-03-29 | — | — | WO | disclosed |
| US-20170362242-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-1951724-A2 | FUSED BICYCLIC mTOR INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007106503-A2 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007061737-A2 | FUSED BICYCLIC mTOR INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061737-A2 | FUSED BICYCLIC mTOR INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| CN-1106783-A | Process | EASTMAN CHEM CO (US) | 1995-08-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119282-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, F2R, F2RL3 | APLNR 240/4885FFAR3 432/4885LMNA 1735/4885 |
| US-20170362242-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | BTK, SYK, ABL1 | APLNR 4873/4885FFAR3 2896/4885LMNA 4305/4885 |
| US-10087188-B2 | Benzamide imidazopyrazine Btk inhibitors | BTK, SYK, ABL1 | APLNR 4873/4885FFAR3 2896/4885LMNA 4305/4885 |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | EGFR, ERBB2, RICTOR | APLNR 3516/4885FFAR3 2637/4885LMNA 4647/4885 |
| US-20250340532-A1 | HETEROCYCLIC COMPOUND CCR4 INHIBITOR AND USER THEREOF | CCR4, CCR1, CCR3 | APLNR 4783/4885FFAR3 1408/4885LMNA 4301/4885 |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | MTOR, MAPKAP1, RPS6KA1 | APLNR 2696/4885FFAR3 3928/4885LMNA 3837/4885 |
| US-10030024-B2 | Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway | F2RL1, F2R, F2RL3 | APLNR 240/4885FFAR3 432/4885LMNA 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.